Antibody-drug Conjugate Information
General Information of This Antibody-drug Conjugate (ADC)
| ADC ID |
DRG0ABCCO
|
|||||
|---|---|---|---|---|---|---|
| ADC Name |
CD74 Milatuzumab DANAPAE152C S375C-P1-L30-P2
|
|||||
| Synonyms |
CD74 Milatuzumab DANAPAE152C S375C-P1-L30-P2
Click to Show/Hide
|
|||||
| Organization |
NOVARTIS AG
|
|||||
| Drug Status |
Investigative
|
|||||
| Drug-to-Antibody Ratio |
4
|
|||||
| Antibody Name |
CD74 Milatuzumab DANAPAE152C S375C
|
Antibody Info | ||||
| Antigen Name |
HLA class II histocompatibility antigen gamma chain (CD74)
|
Antigen Info | ||||
| Payload Name |
P2 payload
|
Payload Info | ||||
| Linker Name |
L30 linker
|
Linker Info | ||||
| Conjugate Type |
Random conjugation through reduced inter-chain cysteines
|
|||||
General Information of The Activity Data Related to This ADC
Full List of Activity Data of This Antibody-drug Conjugate
Revealed Based on the Cell Line Data
| Experiment 1 Reporting the Activity Date of This ADC | [1] | ||||
| Efficacy Data | Half Maximal inhibitory Concentration (lC50) | 0.238 nM | High CD74 expression (CD74 +++) | ||
| Method Description |
CD74 Milatuzumab DANAPAE152C S375C-P1-L30-P2 was tested in EOL-1
|
||||
| In Vitro Model | Chronic eosinophilic leukemia | EoL-1 cells | CVCL_0258 | ||